AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35503145
Drug: Mindfulness practice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness practice at least twice a week
Trial: 34779137
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy with 5% lavender oil
Trial: 34779137
Drug: Placebo massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo massage therapy with baby oil
Trial: 35285912
Drug: IRF-40 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRF-40 (40 mg iron/d)
Trial: 35285912
Drug: IRF-20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRF-20 (20 mg iron/d)
Trial: 35596636
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 and B2 urinary excretion
Trial: 33038271
Drug: 0.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 g/kg alcohol dose
Trial: 33619178
Drug: Probability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probability of vaccine efficacy (50%, 70%, or 90%)
Trial: 33619178
Drug: Announcement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Announcement of vaccines being 95% effective
Trial: 36066264
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal cannula (HFNC) therapy
Trial: 36066264
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy without HFNC
Trial: 33121372
Drug: FF/VI 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100/25 µg
Trial: 36368914
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg·kg‐1 intravenously)
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (canagliflozin) 100 mg/day
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (empagliflozin) 10 mg/day
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (ertugliflozin) 5 mg/day
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (ipragliflozin) 50 mg/day
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (luseogliflozin) 2.5 mg/day
Trial: 35342769
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (tofogliflozin) 20 mg/day
Trial: 32168273
Drug: Pediatric orders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric orders requiring drug formulation manipulation (n=3925)
Trial: 32168273
Drug: Adult orders
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult orders requiring drug formulation manipulation (n=1301)
Trial: 33857028
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (ISMN) 50 mg
Trial: 33164066
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by chemoradiotherapy (Arm B)
Trial: 33164066
Drug: Chemoradiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy with concurrent S-1 (Arm A)
Trial: 32301388
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with low-dose ketamine (0.25mg/kg propofol + 0.15mg/kg ketamine)
Trial: 35409646
Drug: Individualised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised exercise prescription (n = 24)
Trial: 35409646
Drug: Standardised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised exercise prescription (n = 25)
Trial: 36229975
Drug: Baseline sCD163
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline sCD163 ≤ 500 pg/ml
Trial: 33742252
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen (carboxy therapy + intralesional corticosteroids)
Trial: 32166395
Drug: Unilateral subcostal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral subcostal transversus abdominis plane (TAP) block with 20 mL 0.25% bupivacaine
Trial: 32166395
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infiltration at port sites with 20 mL 0.25% bupivacaine
Trial: 34133820
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg every 8 hours for 5 days)
Trial: 34133820
Drug: Ketorolac (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (10 mg every 8 hours for 5 days)
Trial: 34133820
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg every 8 hours for 5 days)
Trial: 34541612
Drug: Sorafenib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib alone or following selective internal radiation therapy (SIRT)
Trial: 33861441
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg) and famotidine (40 mg) daily for 1 month
Trial: 33861441
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and famotidine (40 mg)
Trial: 36910899
Drug: Intrarectal local
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal local anesthesia with 20 mL of heated (40°C) 2% lidocaine gel (n = 50)
Trial: 33933916
Drug: BVDV antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVDV antibody competitive-ELISA assay
Trial: 35803469
Drug: Camostat mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesylate 300 mg three times daily in a fasted state
Trial: 32229229
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical training (PT) group, n = 22, received home‐based supervised muscle strength and endurance training in twice‐weekly 60‐min sessions for 12 weeks
Trial: 33536190
Drug: PI3Kβ inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI3Kβ inhibitor AZD8186
Trial: 33536190
Drug: AKT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT inhibitor MK-2206
Trial: 34007050
Drug: MEK inhibitor
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor selumetinib
Trial: 34978662
Drug: Hybrid decision
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid decision support system using Artificial Intelligence for low-risk prescriptions
Trial: 34978662
Drug: High-risk prescriptions
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk prescriptions
Trial: 34195574
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg per day)
Trial: 35705502
Drug: DIZ101 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIZ101 (intravenous infusion of levodopa/carbidopa)
Trial: 35705502
Drug: DIZ102 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIZ102 (subcutaneous infusion of levodopa/carbidopa)
Trial: 35705502
Drug: LCIG (intestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCIG (intestinal infusion of levodopa/carbidopa)
Trial: 35705502
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (DIZ101, DIZ102, LCIG)
Trial: 35475975
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) decoction, administered twice a day for at least 3 and up to 24 months.
Trial: 34266456
Drug: Leukocyte and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte and platelet-rich fibrin (L-PRF) applied on ulcer beds during twice-weekly dressing changes
Trial: 34266456
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (saline dressings only) during twice-weekly dressing changes
Trial: 35266830
Drug: hNB001 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hNB001 (20 mg to 400 mg)
Trial: 34559684
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil therapy (3% concentration)
Trial: 32014581
Drug: Violet LED
RxNorm normalized name: acid violet 43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Violet LED (VL) irradiation for 30 min, twice per week for three weeks (totaling six sessions)
Trial: 35399071
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction (MBSR) group training, 8 sessions weekly (120-min/session) for 2 months
Trial: 32839527
Drug: Minocycline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 150 mg (twice daily)
Trial: 34987129
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg, bid)
Trial: 34987129
Drug: Control (ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ACEI/ARB and β‐receptor blockers)
Trial: 33849138
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care + music therapy for 60min
Trial: 33093340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cues to medication availability)
Trial: 39415182
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy (ABFT)
Trial: 32228168
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to treatment
Trial: 32681402
Drug: Computer-generated medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-generated medication recommendations
Trial: 39679749
Drug: Small-Quantity Lipid-Based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Trial: 36053828
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (test group)
Trial: 33998210
Drug: CPC loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC loaded with rhBMP‐2 combined with CPC loaded with antibiotic
Trial: 33998210
Drug: CPC loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC loaded with antibiotic
Trial: 33215209
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg/day)
Trial: 32493662
Drug: Continuous magnesium
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous magnesium infusion (10 mmol loading dose of magnesium sulphate followed by 3 mmol/h for up to 96 hours)
Trial: 32493662
Drug: Continuous magnesium
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous magnesium infusion
Trial: 34432203
Drug: Xuezhikang (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (1200 mg/d, orally)
Trial: 34432203
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/d, orally)
Trial: 34632426
Drug: Prophylactic azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic azithromycin (1 g orally) once at baseline
Trial: 34923216
Drug: WATSU therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WATSU therapy combined with land-based therapy
Trial: 34923216
Drug: Land-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based therapy (Control Group)
Trial: 33107945
Drug: Catheter ablation
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation combined with vein of Marshall ethanol infusion
Trial: 34592949
Drug: Epinephrine (BOSMIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (BOSMIN® SOLUTION 0.1%, diluted to 0.02%)
Trial: 34592949
Drug: Tramazoline (TRAMAZOLIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramazoline (TRAMAZOLIN Nasal Solution 0.118%)
Trial: 35759281
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for headache (8 sessions)
Trial: 35759281
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy for PTSD (12 sessions)
Trial: 35759281
Drug: Treatment per
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment per usual (Control)
Trial: 33568368
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral melatonin nightly for 12 weeks
Trial: 33568368
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral melatonin
Trial: 33023498
Drug: Anti-retroviral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-retroviral treatment (ART)
Trial: 34789700
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine injection
Trial: 36103386
Drug: Alfaxalone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (5 mg/kg, IV) + Physiologic saline (0.5 mL, IM)
Trial: 36103386
Drug: Alfaxalone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (5 mg/kg, IM) + Physiologic saline (0.5 mL, IM)
Trial: 36103386
Drug: Medetomidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Trial: 36103386
Drug: Medetomidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Trial: 36103386
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Trial: 36103386
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Trial: 33308198
Drug: Tailored antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored antihypertensive medication based on mean arterial pressure/heart rate ratio
Trial: 35708709
Drug: SMILE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMILE regimen (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Trial: 32491956
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT), 2 sessions applied to pain points with a 48-hr interval
Trial: 32491956
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, 2 sessions applied to pain points with a 48-hr interval
Trial: 32594451
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg OD
Trial: 32594451
Drug: Hydroxychloroquine 300
RxNorm normalized name: hydroxychloroquine 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 300 mg OD
Trial: 32594451
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg OD
Trial: 32594451
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg BD
Trial: 32305572
Drug: 1 ng/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ng/kg LPS intravenous administration
Trial: 32305572
Drug: 2 ng/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ng/kg LPS intravenous administration
Trial: 34319940
Drug: Citrulline-Malate (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline-Malate (8 g CM + 12 g dextrose)
Trial: 35432695
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400mcg
Trial: 35745198
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day bovine lactoferrin (bLF) for 3 weeks (T2)
Trial: 35745198
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day bLF and 2.64 g/day active galactooligosaccharides (GOS) for 3 weeks (T3)
Trial: 35745198
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day bLF, 2.64 g/day GOS and 20 μg/day vitamin D for 3 weeks (T4)
Trial: 33101444
Drug: Qingshen granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingshen granules (three times daily for 12 weeks)
Trial: 33101444
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medical therapy (control group)
Trial: 35716319
Drug: DE-089C (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DE-089C (long-acting diquafosol ophthalmic solution), administered three times daily for 4 weeks
Trial: 35716319
Drug: Placebo ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution, administered three times daily for 4 weeks
Trial: 35942886
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact (SSC) for one hour daily from birth until postnatal week five
Trial: 33096291
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy + PE‐FMR
Trial: 33096291
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy + DE
Trial: 33096291
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy + PE‐FMR + DE
Trial: 35706488
Drug: Active symptom
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active symptom control with oral vinorelbine (ASC + vinorelbine)
Trial: 33431242
Drug: Diabetes medication-taking
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes medication-taking behavior
Trial: 33431242
Drug: Medication-taking behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-taking behavior
Trial: 34106303
Drug: Subcutaneous pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous pertuzumab and trastuzumab (PH FDC SC)
Trial: 34106303
Drug: Intravenous pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous pertuzumab and trastuzumab
Trial: 32725178
Drug: Improving Pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improving Pain During Addiction Treatment (ImPAT)
Trial: 36440097
Drug: Candesartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (up to 32 mg once daily)
Trial: 32761160
Drug: Lisinopril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (up to 40 mg once daily)
Trial: 32727336
Drug: Antithyroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid therapy (thioamides and/or surgical therapy)
Trial: 32727336
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (group 2, n=9)
Trial: 32727336
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (group 1, n=62)
Trial: 33206462
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal ring (25 mg)
Trial: 35477992
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (UFH)
Trial: 35810277
Drug: Ceftriaxone (CRO)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CRO) 1 g IV + Doxycycline (DOX)